

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	ACTINOGEN MEDICAL LIMITED
ABN	14 086 778 476

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Malcolm McComas
Date of appointment	4 April 2019

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
Nil

+ See chapter 19 for defined terms.

Appendix 3X

Initial Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest.	Number & class of Securities
Bunyula Super Pty Ltd <Bunyula Super Fund A/C> - director related entity and contingent beneficial interest	500,000 fully paid ordinary shares

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Director Appointment Letter
Nature of interest	The issue to the Director pursuant to the terms of his appointment of 3,000,000 unlisted options, subject to shareholder approval (if required) on the terms and conditions set out below.
Name of registered holder (if issued securities)	To be Malcolm McComas or his nominee.
No. and class of securities to which interest relates	<p>The exercise price of the options is \$0.10 per option. The options will vest quarterly over a period of 3 years from the date of grant (in each case, subject to his continuous service to the Company as a non-executive director during the period from the date of grant up to and including the applicable vesting date).</p> <p>The options will expire 5 years from the date of commencement of the directorship.</p>

+ See chapter 19 for defined terms.